Sign In
Buy TGTX
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
Why TG Therapeutics Stock Was Tumbling Today
03:37pm, Monday, 05'th May 2025
A near-doubling of revenue and a flip into profitability on the bottom line apparently weren't good enough for TG Therapeutics (TGTX -12.32%) shareholders on Monday.
TG Therapeutics: Share Price Slip On Q1 Earnings Unsurprising Given Challenges
01:30pm, Monday, 05'th May 2025
TG Therapeutics' Q1 2025 earnings report showed strong revenue growth, with Briumvi net revenues rising to $119.7m, prompting an increase in full-year revenue guidance. Despite a >15% drop in stock va
TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript
10:55am, Monday, 05'th May 2025
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Jenna Bosco - Chief Communications Officer Michael Weiss - Chairman and Chief Executiv
TG Therapeutics (TGTX) Lags Q1 Earnings Estimates
09:11am, Monday, 05'th May 2025
TG Therapeutics (TGTX) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to loss of $0.07 per share a year ago.
TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance
07:00am, Monday, 05'th May 2025
First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to appr
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth
11:05am, Wednesday, 30'th Apr 2025
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
07:30am, Wednesday, 30'th Apr 2025
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the fi
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why
12:51pm, Thursday, 10'th Apr 2025
Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is driving the top line.
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
07:30am, Thursday, 10'th Apr 2025
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing for
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms o
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals
07:30am, Monday, 07'th Apr 2025
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple s
These Insurance Stocks And Biotech Leader Hit New Highs As Stock Market Crumbles
03:22pm, Friday, 21'st Mar 2025
Insurance stock Root soared to a new high on Friday. The IBD 50 holding has an ideal Composite and Relative Strength Rating.
Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher
11:50am, Friday, 21'st Mar 2025
Trading is subdued with TG Therapeutics, Inc. TGTX on Friday. But the shares remain in an uptrend and there is a good chance the trend will continue.
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?
06:35am, Monday, 17'th Mar 2025
TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increa
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel
08:42am, Saturday, 15'th Mar 2025
Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and has secured strategic partnerships for azer-cel's development in cancer and
